Brief: OpGen Announces Positive Top Line Data From Clinical Trial For Unyvero Urinary Tract Infection Panel
13/12/2022 13:00
Dec 13 (Reuters) - OpGen Inc OPGN.O :
* OPGEN ANNOUNCES POSITIVE TOP LINE DATA FROM CLINICAL TRIAL
FOR
UNYVERO URINARY TRACT INFECTION PANEL
* OPGEN - CLINICAL PERFORMANCE RESULTS WILL BE USED TO
PREPARE
SUBMISSION PACKAGE FOR FDA DE NOVO REQUEST
* OPGEN - PRIMARY ENDPOINT FOR UNYVERO UTI FOR URINARY TRACT
INFECTION SHOWS OVERALL WEIGHTED AVERAGE SENSITIVITY OF 96.4% IN
PRELIMINARY ANALYSIS
Source text for Eikon: ID:nGNX3zWPxg
Further company coverage: OPGN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CapForce
See all newsBrief: Opgen Says Financial Statements Contained Within Quarterly Report On Form 10-Q For Q1 2024 Should No Longer Be Relied Upon
Brief: Opgen Inc - Received Nasdaq Notice That Co Is Not In Compliance With Minimum Stockholders' Equity Requirement For Continued Listing
Brief: OpGen Receives Expected Nasdaq Notice Regarding Delayed Form 10-Q
Brief: OpGen Announces 1-For-10 Reverse Stock Split
Brief: David E. Lazar Reports 19.9% Stake In Opgen Inc As Of March 25- SEC Filing